Phase 2 N=100 Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
Non-small Cell Lung Cancer
Primary: 2-year Disease-free Survival — 88 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=168 S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: 2-year Overall Survival Rate — 67; 70 percentage of participants — p=0.44
Phase 4 N=60 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Carcinoma, Non-Small-Cell Lung
Primary: Objective Tumour Response (Complete Response [CR], Partial Response [PR]) as Assessed by the Investigator According to the RECIST Version 1.1 — 50 Percentage of…
Phase 2 N=17 A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
Non Small Cell Lung Cancer
Primary: Objective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) — 8 Participants
Phase 4 N=24 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) Among Erlotinib-Treated Participants With the EGFR Mutation — 13.7 months
Phase 3 N=219 Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.7; 4.2 months
Phase 3 N=542 Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Serious Adverse Events (SAEs) — 30.3 Percentage of participants (%)
Phase 2 N=88 Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
EGFR Exon 19 Deletion Mutation · EGFR NP_005219.2:p.L858R · Lung Non-Squamous Non-Small Cell Carcinoma
Primary: Progression Free Survival (PFS) — 13.5; 17.9 months — p=0.39
Phase 2 N=9 Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)
Non Small Cell Lung Cancer · Lung Cancer
Primary: Number of Patients With Pathologic Complete Response Rate — 1; 1; 2; 2 participants
Phase 2 N=30 A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response (Complete Response [CR]/Partial Response [PR]) Based on Computer Tomography (CT) or Magnetic Resonance Imaging (MRI)…
Phase 2 N=6 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression-free Survival (Tumour Assessments According to RECIST Criteria) — 223 Days
Phase 3 N=217 A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
Non-Small Cell Lung Cancer
Primary: Investigator-assessed Duration of Progression-free Survival — 11.0; 5.5 Months
Phase 2 N=688 A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Tested Positive for EGFR Mutations — 8.1 percentage of participants
Phase 2 N=23 A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate (ORR) — 18.2 Percentage of Participants
Phase 3 N=14 Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations
Carcinoma, Non-Small-Cell Lung
Primary: Safety Assesment — 92.9; 35.7; 35.7; 21.4 Percentage of participants
Phase 3 N=174 Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR
Non-Small Cell Lung Cancer
Primary: Progression Free-survival — 9.4; 5.2 months — p=0.0001
Phase 4 N=62 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 12.846 Months
Phase 2 N=186 Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone
Non Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 10.9; 10.9 Month — p=0.124
Phase 2 N=23 A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations
Carcinoma，Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS), as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 387.000 days
N/A N=462 The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
Non-squamous, Non-Small Cell Lung Cancer
Primary: Time on Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) — 9.89; 27.7 Months
Phase 2 N=11 Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer
Stage IIIA Non-Small Cell Lung Cancer · Stage IIIB Non-Small Cell Lung Cancer · Stage IV Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) Determined as the Percentage of Patients Achieving Complete Response or Partial Response as Respectively Defined in RECIST 1.1 — 1 Participants
Phase 3 N=375 A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v 1.1) — 9.574 months
Phase 2 N=208 A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression-free Survival Per RECIST, v. 1.1 (PFS1) — 11.000 months
Phase 2 N=60 Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
Non-small Cell Lung Cancer
Primary: Resistance Mechanism — 23; 1; 3; 4 participants
Phase 2 N=210 Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours
Non Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 70.9 % of participants
N/A N=4 Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
Oligometastatic Lung Adenocarcinoma
Primary: Feasibility as Measured by at Least Five Patients Will Need to Complete Local Therapy.
Phase 4 N=107 Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Primary: Objective Response Rate (ORR) (Investigator) — 69.8; 30.2 Percentage of Participants
Phase 2 N=15 Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
Locally Advanced or Metastatic NSCLC
Primary: Objective Response Rate — 0 Participants
N/A N=72 The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer
Non-squamous, Non-Small Cell Lung Cancer
Primary: Time on Treatment of Afatinib as First-line Therapy in Advanced Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Mutation — 14.4 Months
Phase 3 N=1,250 A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
Non-small Cell Lung Cancer
Primary: Disease Free Survival (DFS) — 50.5; 48.2 months — p=0.3235